Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 8Breast Neoplasms 8Carcinoma, Ovarian Epithelial 4Carcinoma, Non-Small-Cell Lung 4Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Esophageal Squamous Cell Carcinoma 2Carcinoma 2Uterine Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thrombocytopenia 1Primary Breast Cancer 1Pharyngeal Neoplasms 1Penile Neoplasms 1Pathologic Complete Response 1Paranasal Sinus Neoplasms 1Ovarian Diseases 1Neutropenia 1Neoplasms, Unknown Primary 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Breast Cancer × CP protocol × Clear all
NCT01314833 2020-05-19

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Fudan University

Phase 3 Completed
1,570 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡